Warren, NJ and Portage, Ind. (May 28, 2008) – MonoSol Rx, a drug delivery company specializing in dissolving thin film pharmaceutical products, announced today the appointment of John McCracken as Senior Vice President, Business Development. Mr. McCracken will report to Keith J. Kendall, Executive Vice President and CFO.
Mr. Kendall commented, “We are pleased to welcome John to MonoSol Rx’s executive team. John’s leadership will be invaluable as we continue to target partnership and development opportunities for our thin film drug delivery technology. Having established a clear leadership position in the thin film market, MonoSol Rx is now focused on increasing the commercial use of thin film for drug applications while bringing new pharmaceutical products to market that enhance the delivery and effectiveness of existing and new compounds.”
Mr. McCracken comes to MonoSol Rx after serving as Executive Director of Business Development & International for Watson Pharmaceuticals. While at Watson Pharmaceuticals, Mr. McCracken was responsible for international licensing and managed over twenty licensing relationships. Prior to that, Mr. McCracken was Vice President, Business Development of DOR BioPharma, Inc., a drug delivery company focused on oral delivery of injectable drugs. Before his tenure at DOR BioPharma, Mr. McCracken held various positions at G.D. Searle, including Global Operations Director, Managing Director, SE Asia & Asia Pac Business Development, and Executive Director, International Operations. In addition, he spent four years with Abbott Laboratories in various finance positions.
About MonoSol Rx
MonoSol Rx is a drug delivery company specializing in proprietary, dissolving thin film pharmaceutical products. The Company’s thin film technology, which is similar in size, shape and thickness to a postage stamp, dissolves rapidly and utilizes a novel process and proprietary encapsulation compositions to mask the taste of the drug contained within the film. MonoSol Rx’s strategy is to develop and partner innovative thin film strip products in the prescription, generic and OTC pharmaceutical markets and to establish a leadership position in thin film drug delivery technology through continued development of its drug delivery technology and intellectual property portfolio.